Trade Summary

3 days ago, Seehra Jasbir, serving as CEO at Keros Therapeutics, Inc. (KROS), sold 7,015 shares at $16.17 per share, for a total transaction value of $113,433.00. Following this transaction, Seehra Jasbir now holds 385,708 shares of KROS.

This sale represents a 2.00% decrease in Seehra Jasbir's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, February 19, 2026 and publicly disclosed via SEC Form 4 filing on Friday, February 20, 2026, 1 day after the trade was made.

Keros Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.